Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 22:12:927640.
doi: 10.3389/fonc.2022.927640. eCollection 2022.

The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer

Xiaoge Hu  1   2   3 , Xiangxiang Lei  4 , Jinhui Guo  5 , Wen Fu  5 , Wen Sun  6 , Qiliang Lu  5 , Wei Su  7 , Qiuran Xu  2 , Kangsheng Tu  1
Affiliations
Review

The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer

Xiaoge Hu et al. Front Oncol. .

Abstract

Pancreatic cancer (PC) is one of the most common malignant cancers, ranking the seventh highest causes of cancer-related deaths globally. Recently, RNA N6-methyladenosine (m6A) is emerging as one of the most abundant RNA modifications in eukaryote cells, involved in multiple RNA processes including RNA translocation, alternative splicing, maturation, stability, and degradation. As reported, m6A was dynamically and reversibly regulated by its "writers", "erasers", and "readers", Increasing evidence has revealed the vital role of m6A modification in the development of multiple types of cancers including PC. Currently, aberrant m6A modification level has been found in both PC tissues and cell lines. Moreover, abnormal expressions of m6A regulators and m6A-modified genes have been reported to contribute to the malignant development of PC. Here in this review, we will focus on the function and molecular mechanism of m6A-modulated RNAs including coding RNAs as well as non-coding RNAs. Then the m6A regulators will be summarized to reveal their potential applications in the clinical diagnosis, prognosis, and therapeutics of PC.

Keywords: N6-methyladenosine (m6A); RNA methylation; coding RNAs; non-coding RNAs; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The dynamic regulation of m6A modification in RNAs.
Figure 2
Figure 2
Regulation network of m6A regulators and associated genes in pancreatic cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic Cancer. Lancet (2020) 395(10242):2008–20. doi: 10.1016/S0140-6736(20)30974-0 - DOI - PubMed
    1. Khan AA, Liu X, Yan X, Tahir M, Ali S, Huang H. An Overview of Genetic Mutations and Epigenetic Signatures in the Course of Pancreatic Cancer Progression. Cancer Metastasis Rev (2021) 40(1):245–72. doi: 10.1007/s10555-020-09952-0 - DOI - PubMed
    1. Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, et al. . Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines (2021) 9(4):373. doi: 10.3390/biomedicines9040373 - DOI - PMC - PubMed
    1. Barbieri I, Kouzarides T. Role of RNA Modifications in Cancer. Nat Rev Cancer (2020) 20(6):303–22. doi: 10.1038/s41568-020-0253-2 - DOI - PubMed